
Fennec Pharmaceuticals (FENC) Stock Forecast & Price Target
Fennec Pharmaceuticals (FENC) Analyst Ratings
Bulls say
Fennec Pharmaceuticals is benefiting from accelerating adoption of PEDMARK as the expanded commercial organization drives deeper utilization, higher vials per account, and stronger demand across new and existing accounts, with 2Q26 net product sales rising to $17.2M, up 78% year over year. Its outlook is further supported by improving operating leverage, as total revenue reached $17.9M in 2Q26, non-GAAP adjusted EBITDA turned positive at $2.8M, and cash and equivalents stood at $41.2M, signaling a stronger financial base. Longer-term upside also comes from potential NCCN reclassification by early 2028 and possible Japan entry in 2027, while the absence of current European revenue leaves room for additional royalty and international contribution.
Bears say
Fennec Pharmaceuticals is exposed to a highly fragile investment case because 100% of revenue comes from PEDMARK, leaving no pipeline diversification and forcing any expansion to depend on external partnerships or dilutive financing. Patent litigation risk is especially damaging because an unfavorable outcome could shorten exclusivity, while commercial growth still hinges on faster AYA account activation, formulary access, and reimbursement support despite pediatric economics that favor compounded STS at 70-90% discounts. Financially, cash was $42M as of December 2025, but the ongoing commercial buildout raises the cost base and leaves the company vulnerable if revenue underperforms, increasing the likelihood of further capital needs and volatility.
This aggregate rating is based on analysts' research of Fennec Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Fennec Pharmaceuticals (FENC) Analyst Forecast & Price Prediction
Start investing in Fennec Pharmaceuticals (FENC)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Fennec Pharmaceuticals (FENC) Forecast
Fennec Pharmaceuticals (FENC) Analyst Forecast & Price Prediction
Start investing in Fennec Pharmaceuticals (FENC)
Order type
Buy in
Order amount
Est. shares
0 shares